Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Comparing access to orphan medicinal products in Europe

Fig. 1

Comparison of access to OMPs. Notes: * 143 OMPs obtained a marketing authorisation since the implementation of the EU Regulation on Orphan. Medicines (Regulation (EC) No 141/2000). † OMPs reimbursed refers to Health Technology Assessment (HTA) recommendations to use or inclusion in reimbursement lists in respective national health systems

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172